Spastic paraplegia 11

From WikiMD's Food, Medicine & Wellness Encyclopedia

Alternate names[edit | edit source]

SPG11; Hereditary spastic paraplegia mental impairment and thin corpus callosum; Autosomal recessive spastic paraplegia type 11; Hereditary spastic paraplegia 11; Nakamura Osame syndrome; Spastic paraplegia - intellectual deficit - thin corpus callosum

Definition[edit | edit source]

Spastic paraplegia 11 (SPG11) is a form of hereditary spastic paraplegia. People with SPG11 experience worsening muscle stiffness leading to eventual paralysis of the lower limbs, as well as a range of other neurologic symptoms that may include intellectual disability, speech difficulties (dysarthria), and reduced bladder control.

Cause[edit | edit source]

SPG11 is caused by mutations in the SPG11 gene.

Inheritance[edit | edit source]

Autosomal recessive inheritance, a 25% chance

SPG11 is inherited in an autosomal recessive manner. This means that to be affected, a person must have a mutation in both copies of the responsible gene in each cell. Affected people inherit one mutated copy of the gene from each parent, who is referred to as a carrier. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:

  • 25% (1 in 4) chance to be affected
  • 50% (1 in 2) chance to be an unaffected carrier like each parent
  • 25% chance to be unaffected and not be a carrier

Onset[edit | edit source]

  • Age at time of symptom onset varies from infancy to early adulthood, with onset in infancy to adolescence being most common.
  • Learning disability may begin in childhood.
  • Most people experience a decline in intellectual ability and an increase in muscle weakness and nerve abnormalities over time.
  • As the condition progresses, some people require wheelchair assistance (often 10 to 20 years after symptom onset).

Signs and symptoms[edit | edit source]

Signs and symptoms of SPG11 may include:

  • Spasticity (progressive muscle stiffness)
  • Paraplegia(eventual paralysis of the lower limbs)
  • Numbness, tingling, or pain in the arms and legs
  • Disturbance in the nerves used for muscle movement
  • Intellectual disability
  • Exaggerated reflexes of the lower limbs
  • Speech difficulties (dysarthria)
  • Reduced bladder control (Muscle wasting)

Less common features, include:

  • Difficulty swallowing (dysphagia)
  • High-arched feet
  • Scoliosis
  • Involuntary movements of the eyes

Diagnosis[edit | edit source]

The diagnosis of SPG11 is established in a proband with characteristic clinical and MRI findings and biallelic pathogenic variants in SPG11 identified on molecular genetic testing.[1][1].

Treatment[edit | edit source]

  • Care for SPG11 is usually managed by a team including a primary care physician, neurologist, genetics professional (geneticist and/or genetic counselor), physical therapist, social worker, and psychologist.
  • Treatment is focused on alleviating symptoms and may include:
  • Medications for leg spasticity (antispastic drugs)
  • Medications to assist in bladder control (anticholinergic antispasmodic drugs)
  • Regular physician therapy
  • Botulinum toxin and intrathecal baclofen for severe spasticity
  • Regular outpatient clinic evaluations are recommended to adjust medications and physical therapy/rehabilitation routines.
  • Routine brain MRI and electrophysiological investigations (muscle and nerve studies) may be useful to follow the progression of the disease.

Prognosis[edit | edit source]

The severity of symptoms in SPG11 worsen over time, with most individuals experiencing full clinical symptoms 10 years after onset. Most individuals with SPG11 require wheelchair assistance 10-20 years after onset. Intellectual disability and cognitive decline additionally typically worsen over time and may include short-term memory impairment, constant fluctuations in emotions, reduced verbal abilities, and attention deficits.


NIH genetic and rare disease info[edit source]

Spastic paraplegia 11 is a rare disease.


Spastic paraplegia 11 Resources
Doctor showing form.jpg
  1. Stevanin G. Spastic Paraplegia 11. 2008 Mar 27 [Updated 2019 Dec 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1210/
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD